专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07879320B2 Hydrogel interferon formulations 失效
标题翻译：水凝胶干扰素制剂
公开(公告)号：US07879320B2
公开(公告)日：2011-02-01
申请号：US11596599
申请日：2005-05-13
申请人： Maria Dorly Del Curto , Ilaria Zambaldi , Silvia Pompili , Pierandrea Esposito
发明人： Maria Dorly Del Curto , Ilaria Zambaldi , Silvia Pompili , Pierandrea Esposito
IPC分类号： A61K38/21 , A61K38/19 , C07K14/52
CPC分类号： A61K38/13 , A61K9/0014 , A61K38/21 , A61K38/215 , A61K47/10 , A61K47/34 , A61K2300/00
摘要： The present invention is related to pharmaceutical Poloxamer hydrogel formulations containing an interferon. In particular, the invention relates to sustained release hydrogel formulations of interferon-beta, method of preparation and use thereof.
摘要翻译：本发明涉及含有干扰素的药物泊洛沙姆水凝胶制剂。特别地，本发明涉及干扰素-β的持续释放水凝胶制剂，其制备方法和用途。

2. 发明授权

US06495160B2 Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs 失效
标题翻译：含有能够改变药物分配的物质的双相多组分药物剂型
公开(公告)号：US06495160B2
公开(公告)日：2002-12-17
申请号：US09214813
申请日：1999-10-01
申请人： Pierandrea Esposito , Nicoletta Coceani , Maria Dorly Del Curto , Fabio Carli
发明人： Pierandrea Esposito , Nicoletta Coceani , Maria Dorly Del Curto , Fabio Carli
IPC分类号： A61K970
CPC分类号： A61K9/06 , A61K47/22
摘要： The invention provides a biphasic multicomponent pharmaceutical composition consisting of an oil phase and a water phase, comprising one or more lipophilic or oil carrier, one or more hydrophilic or aqueous carrier, one or more ionic or nonionic type surfactant, one or more cosurfactant, one or more active principle for pharmaceutical use, and a compound able to modify the partition of the active principle between said phases selected from the group consisting of N- methyl pyrrolidone (NMP), isopropyl alcohol, propylene glycol, ethoxy-di-glycol, &bgr;-cyclodextrin, hydroxypropyl &bgr;-cyclodextrin and dimethyl &bgr;-cyclodextrin. The invention also provides a method for making the composition.
摘要翻译：本发明提供由油相和水相组成的双相多组分药物组合物，其包含一种或多种亲脂性或油载体，一种或多种亲水或水性载体，一种或多种离子型或非离子型表面活性剂，一种或多种辅助表面活性剂，一种或更有效的药物用途原理，以及能够改变选自N-甲基吡咯烷酮（NMP），异丙醇，丙二醇，乙氧基 - 二醇，β的所述相之间活性成分分配的化合物环糊精，羟丙基β-环糊精和二甲基β-环糊精。本发明还提供了制备组合物的方法。

3. 发明授权

US07704525B2 Lipid microparticles by cryogenic micronization 失效
标题翻译：脂质微粒通过低温微粉化
公开(公告)号：US07704525B2
公开(公告)日：2010-04-27
申请号：US10451676
申请日：2001-12-17
申请人： Maria Dorly Del Curto , Daniela Chicco , Pierandrea Esposito
发明人： Maria Dorly Del Curto , Daniela Chicco , Pierandrea Esposito
IPC分类号： A61K9/127 , A61K38/08 , A61K38/21 , A61K9/14
CPC分类号： A61K38/08 , A61K9/145 , A61K9/1617 , A61K38/215
摘要： This invention relates to Lipid Microparticles consisting of lipids enriched in amphiphilic components, which promote the incorporation of peptides and/or protein, process for obtaining them as well as use thereof. A cryogenic micronization manufacturing process for their preparation is also disclosed.
摘要翻译：本发明涉及由富含两亲性成分的脂质组成的脂质微粒，其促进肽和/或蛋白质的并入，获得它们的方法及其用途。还公开了一种用于其制备的低温微粉化制造方法。

4. 发明申请

US20110250238A1 SYSTEM FOR THE COLON DELIVERY OF DRUGS SUBJECT TO ENZYME DEGRADATION AND/OR POORLY ABSORBED IN THE GASTROINTESTINAL TRACT 审中-公开
标题翻译：用于胃肠道递送和/或吸收在胃肠道诱导中的药物递送的系统
公开(公告)号：US20110250238A1
公开(公告)日：2011-10-13
申请号：US13054149
申请日：2009-07-17
申请人： Maria Edvige Sangalli , Gianaldo Tavella , Maria Dorly Del Curto , Andrea Gazzaniga , Alessandra Maroni , Luca Palugan , Lucia Zema , Maddalena Spreafico
发明人： Maria Edvige Sangalli , Gianaldo Tavella , Maria Dorly Del Curto , Andrea Gazzaniga , Alessandra Maroni , Luca Palugan , Lucia Zema , Maddalena Spreafico
IPC分类号： A61K9/00 , A61K38/28 , A61P1/00 , A61K31/575 , A61P3/10 , A61K38/02 , A61K31/24
CPC分类号： A61K9/209 , A61K9/2853 , A61K9/2886 , A61K31/167 , A61K31/24 , A61K38/28 , A61K45/06 , A61K2300/00
摘要： Said invention refers to a pharmaceutical form for selective colon delivery of drugs or bioactive molecules degraded and/or poorly absorbed in the gastrointestinal tract. The system comprises a core consisting of the active ingredient, and a protease inhibitor layer and/or an absorption enhancer layer, said core being separated from these layers by means of a polymer that swells and/or dissolves and/or is degraded when in contact with the biological fluids present in the gastro-intestinal tract; depending on the thickness of the polymeric layer, the release of the drug can be modulated with respect to the inhibitor and/or promoter.
摘要翻译：所述发明涉及用于选择性结肠递送在胃肠道中降解和/或吸收不良的药物或生物活性分子的药物形式。该系统包括由活性成分和蛋白酶抑制剂层和/或吸收增强剂层组成的核心，所述核心通过在接触时溶胀和/或溶解和/或降解的聚合物与这些层分离生物流体存在于胃肠道中; 取决于聚合物层的厚度，可以相对于抑制剂和/或启动子调节药物的释放。

5. 发明授权

US07846427B2 Stabilized interferon liquid formulations 有权
标题翻译：稳定的干扰素液体制剂
公开(公告)号：US07846427B2
公开(公告)日：2010-12-07
申请号：US10582027
申请日：2004-12-10
申请人： Maria Dorly Del Curto
发明人： Maria Dorly Del Curto
IPC分类号： A61K38/21 , A61K38/00 , C07K14/565
CPC分类号： A61K38/215 , A61K47/183 , A61K47/26 , A61K47/40
摘要： Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the cyclodextrin is HPBCD. These formulations are stable at room temperature, thus bringing the advantage of lower costs for formulation storage and increased safety for the patient with respect to possible “errors” during handling. As a matter of fact, having such formulations stable at room temperature reduces the risk of formation of degradation products potentially responsible for adverse events (e.g. immunogenicity).
摘要翻译：包含干扰素（IFN）或同工型，突变蛋白，融合蛋白，功能衍生物，活性成分或其盐的稳定液体药物组合物，其中所述制剂是包含缓冲液，环糊精，等渗剂和抗氧化剂在这里描述。干扰素优选为干扰素β-1a，环糊精为HPBCD。这些制剂在室温下是稳定的，因此带来了降低制剂储存成本和增加患者对于处理过程中可能“错误”的安全性的优点。事实上，使这种制剂在室温下稳定降低了潜在地对不利事件（例如免疫原性）负责的降解产物的形成风险。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式